SHR2554 plus hormone therapy for advanced breast cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug (SHR2554) combined with standard hormone therapy for people with advanced or metastatic breast cancer. The goal is to see if the combination helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced or metastatic breast cancer (cancer that has spread).
- You are physically active (ECOG score 0-1), meaning you can do most daily activities.
- You have at least one measurable tumor that can be seen on scans.
- You have not had certain types of prior treatment (like ADC therapy) and are willing to avoid certain medications during the trial.
- You have no uncontrolled brain metastases or serious heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combined with other anti-cancer drugs for advanced breast cancer. The goal is to see if the combination can shrink tumors and help people live longer, and if it is safe.
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
This study tests two new experimental drugs (HRS-4642 and SHR-A2102) given together to people with advanced solid tumors. The goal is to see if the combination is safe and helps shrink tumors or slow their growth.
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This trial tests a new drug, HRS-7058, combined with other anti-cancer drugs for people with advanced solid tumors that cannot be surgically removed. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a new drug (SHR-A1811) combined with fulvestrant, with or without another drug (HS-10352), for people with advanced breast cancer that has not been treated before. The goal is to see if these combinations can help control the cancer.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.